This peritoneal-specific immune modulation mechanism may also happen in other types of cancers that can disseminate into the peritoneal cavity, such as gastric cancer, endometrial carcinoma, colon cancer, and bladder carcinoma, in which the high expression of IL20RA also correlates with a better clinical outcome of patients (Figure 2—figure supplement 1), highlighting the importance of IL-20/IL20RA-mediated epithelial immunity in preventing cancer metastasis into the peritoneal environment. The gene discussed is IL20; the disease is endometrial carcinoma.